GLP2

Tirzepatide works by reducing appetite, increasing the feeling of fullness, and slowing gastric emptying, which helps with weight loss.

It is a GIP and GLP-1 receptor agonist and works like both of our natural hormones, GIP and GLP-1. Normally, when we eat, natural hormones called GIP and GLP-1 are released by the gut. 

It works by suppressing appetite, slowing gastric emptying, increasing the feeling of fullness, and increasing insulin release and insulin sensitivity. 

Tirzepatide works (mechanism of action) by activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation[2].

Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.

Dose Range: 2.5–15 mg weekly with 4‑week titration intervals.

Reconstitution: 2.0 mL per 10 mg vial (5.0 mg/mL) for manageable injection volumes.

Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.

Dosing Protocol

Suggested weekly titration approach.

Start: 2.5 mg once weekly for 4 weeks (initiation dose)[1].

Escalate: Increase by 2.5 mg every 4 weeks as tolerated.

Maintenance: 5–15 mg weekly based on response and tolerability.

Frequency: Once per week (subcutaneous), same day each week.

Timing: Any time of day; with or without food; rotate injection sites.